阿尼卡疗法 ANIK 深 沪
等待开盘 03-26 09:30:00 美东时间
14.56
+0.280
+1.96%
华盛通- 最 高14.63
- 今 开14.43
- 成交量 13.85万股
- 最 低 14.40
- 昨 收 14.28
- 总市值 1.95亿
- 52周最高 15.13
- 市盈率 静 --
- 换手率 1.03%
- 52周最低 7.8701
- 委 比 1.89%
- 总股本 1340.08万
- 历史最高 75.715
- 量 比 1.06
- 振 幅 1.61%
- 历史最低 5.24
- 每 手 1
- 风险率 2.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anika Therapeutics Earnings Call Signals Cautious Rebound
Anika Therapeutics, Inc. (($ANIK)) has held its Q4 earnings call. Read on for t...
03-08 08:25
Top 2 Health Care Stocks That May Crash This Quarter
2 stocks in healthcare sector flashing warning to investors who value momentum. RSI is an indicator that compares stock strength on up and down days.
03-04 21:55
Anika Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
Anika Therapeutics shares are trading higher after the company reported better-...
02-27 01:11
Insights into Anika Therapeutics Q4 Earnings
Anika Therapeutics (NASDAQ:ANIK) announced its Q4 earnings on Thursday, Februar...
02-26 20:08
Anika Therapeutics Sees FY2026 Sales $114.000M-$122.500M vs $116.351M Est
Fiscal 2026 GuidanceAnika is providing the following 2026 guidance:Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over yearCommercial Channel, $53 to $58 million, maintaining up 10% to 20% year
02-26 20:08
Anika Therapeutics Q4 Adj. EPS $0.31 Beats $(0.21) Estimate, Sales $30.615M Beat $28.875M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.21) by 244.19 percent. This is a 1133.33 percent increase over losses of $(0.03) per share
02-26 20:07
BRIEF-Anika Therapeutics Q4 Revenue USD 30.615 Million
BRIEF-Anika Therapeutics Q4 Revenue USD 30.615 Million Feb 26 (Reuters) - Anika Therapeutics Q4 pretax profit USD 764 thousand. Q4 income from operations USD 646 thousand Q4 gross profit USD 19.179 million Q4 net income USD 292 thousand
02-26 20:05
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Anika Therapeutics的总裁兼首席执行官Steve Griffin将在2026年3月2日参加Canaccord Genuity在新奥尔良举办的骨科大会并发表演讲。演讲时间为美国中部时间上午11:30，东部时间下午12:30。演讲将通过Anika官方网站的投资者页面进行直播，并在结束后30天内提供存档。投资者可联系investorrelations@anika.com安排会议。
02-18 21:01
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
